ESMO Virtual Congress 2020 Lung Cancer In-depth

Characterization of Predictors of Response or Resistance to ICIs in NSCLC

PD-L1 expression density and cytotoxic T cells were identified as potential biomarkers for outcomes with ICIs in patients with NSCLC.

Apatinib Plus Gefitinib Improved PFS in EGFR-Mutated NSCLC

The addition of apatinib to gefitinib prolonged PFS compared with gefitinib among treatment-naive patients with EGFR-mutated NSCLC.

No Benefit, Higher Toxicities With Postoperative Conformal RT in Stage IIIAN2 NSCLC

The use of modern postoperative conformal radiotherapy did not improve DFS and was associated with toxicities among patients with stage IIIAN2 NSCLC.

Longitudinal NGS May Identify Patients At Risk for Hyperprogression or Death From ICIs

NGS of longitudinal samples from patients with advanced NSCLC receiving ICIs identified changes associated with hyperprogression and early death.

KRAS Inhibitor Shows Favorable Activity in Advanced NSCLC

Results from a phase 1 trial suggest a KRASG12C inhibitor has a favorable safety profile and antitumor activity in advanced NSCLC.

Characteristics and Treatment Patterns of KRASG12C-Mutated NSCLC

An analysis of from the Flatiron Health Network found that some patients with NSCLC with a KRASG12C mutation do not receive systemic therapy.